defense-tech is the sole category represented across all 1 tracked stories. Lunai Bioworks is most often covered alongside AI Antidote Development Model, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lunai Bioworks
defense-tech is the sole category represented across all 1 tracked stories. Lunai Bioworks is most often covered alongside AI Antidote Development Model, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 7 runs below the beat's 7.2 for that window. Lunai Bioworks appears in 1 tracked Space & Defense story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Space & Defense stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lunai Bioworks. Shared-story counts are live from our verified record — not editorial picks.
Lunai Bioworks (NASDAQ: LNAI) has established the National Chemical Defense Consortium to pursue up to $1.2 billion in U.S. defense countermeasure programs. The initiative utilizes a proprietary 3-year AI development model to drastically accelerate the creation of antidotes for chemical threats.